

# Validation data for Jurkat-Lucia™ hICOS Cells


<https://www.invivogen.com/jurkat-lucia-icos>

For research use only

Version 23L12-NJ


Jurkat-Lucia™-hICOS cells were designed for the screening of novel agonists of immune checkpoint ICOS (inducible co-stimulator). They overexpress a human ICOS-CD3 $\zeta$  fusion protein and an NFAT-inducible Lucia luciferase reporter gene. The surface overexpression of human ICOS in these cells compared to their parental cell line has been validated using flow cytometry (Figure 1). In the presence of a potent ICOS agonist, such as hICOS-L-Fc, hICOS-CD3 $\zeta$  triggers NFAT activation and Lucia production (Figure 2).

## ICOS overexpression on Jurkat-Lucia™ hICOS cells



**Figure 1: Validation of human ICOS overexpression by Jurkat-Lucia™hICOS cells.** Jurkat-Lucia™ NFAT and Jurkat-Lucia™ hICOS cells were incubated with a PE-conjugated Anti-hICOS mAb for 30 minutes. The binding affinity was measured using flow cytometry. Unstained cells are shown in grey.

## Activation of Jurkat-Lucia™-hICOS cells using ICOS agonists



**Figure 3: Activation of Jurkat-Lucia™-hICOS cells.** Jurkat-Lucia™-hICOS cells were incubated with increasing concentrations of recombinant human ICOS-L-Fc fusion protein, agonist Anti-hICOS armenian hamster IgG, or control Anti-βGal hlgG1 monoclonal antibodies for 6 hours. NFAT activation in the Jurkat-Lucia™-hICOS cells was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™ 4 Reagent. Fold responses are shown as mean + SEM.

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873  
InvivoGen USA (International): +1 (858) 457-5873  
InvivoGen Europe: +33 (0) 5-62-71-69-39  
InvivoGen Asia: +852 3622-3480  
E-mail: [info@invivogen.com](mailto:info@invivogen.com)



Any questions about our cell lines?  
Visit our FAQ page.

 **InvivoGen**  
[www.invivogen.com](http://www.invivogen.com)